Takeda gives Affymax $10M milestone payment for anemia therapy

08/10/2011 | Forbes

Takeda Pharmaceutical paid a $10 million milestone fee to Affymax after the FDA accepted a marketing application for anemia drug candidate peginesatide. The companies aim to co-promote the drug to anemic patients with chronic renal failure.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR